GRAND CAYMAN – When considering the use of biologic therapy for psoriasis patients who are at greater risk of cancer or of serious infection, Dr. Kenneth B. Gordon advises clinicians to “look at the patient in front of you” and the impact the disease is having on them.
In an interview at the annual Caribbean Dermatology Symposium, Dr. Gordon, professor of dermatology at Northwestern University, Chicago, discusses the use of biologics to treat psoriasis in patients with a history of cancer, patients at an increased risk for serious infections (such as those with chronic renal disease or diabetes), as well as patients with HIV, who can have significant psoriasis.
He also provides some recommendations on counseling patients and discusses the use of biologics in children with psoriasis.
The meeting is provided by Global Academy for Medical Education. Global Academy and this news organization are owned by the same parent company.
On Twitter @whitneymcknight
This article was updated 1/31/2016.